TR201910084T4 - Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri. - Google Patents

Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri. Download PDF

Info

Publication number
TR201910084T4
TR201910084T4 TR2019/10084T TR201910084T TR201910084T4 TR 201910084 T4 TR201910084 T4 TR 201910084T4 TR 2019/10084 T TR2019/10084 T TR 2019/10084T TR 201910084 T TR201910084 T TR 201910084T TR 201910084 T4 TR201910084 T4 TR 201910084T4
Authority
TR
Turkey
Prior art keywords
formula
radioactive
prostate specific
specific membrane
membrane antigen
Prior art date
Application number
TR2019/10084T
Other languages
English (en)
Inventor
W Babich John
Zimmerman Craig
L Joyal John
Lu Genliang
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Publication of TR201910084T4 publication Critical patent/TR201910084T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages

Abstract

Formül I'e ve Formül II'ye göre bileşikler PSMA aktivitesinin güçlü inhibitörleridir: Buluş ayrıca, bir radyonüklidin ve bir Formül I bileşiğinin veya bir Formül II bileşiğinin bir kompleksinin farmasötik bileşimlerini ve PSMA aktivitesi ile ilişkilendirilmiş bir hastalığı veya bir rahatsızlığı tedavi etme veya bunun tanısı için bir Formül I bileşiğinin veya bir Formül II bileşiğinin radyonüklid kompleksini kullanmanın yöntemlerini de sağlar.
TR2019/10084T 2011-08-05 2012-08-03 Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri. TR201910084T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515674P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
TR201910084T4 true TR201910084T4 (tr) 2019-08-21

Family

ID=47627059

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10084T TR201910084T4 (tr) 2011-08-05 2012-08-03 Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri.

Country Status (10)

Country Link
US (2) US8926944B2 (tr)
EP (2) EP3505192A1 (tr)
JP (1) JP5843338B2 (tr)
AU (1) AU2012294639B2 (tr)
CA (1) CA2844151C (tr)
ES (1) ES2732060T3 (tr)
HU (1) HUE045028T2 (tr)
PL (1) PL2739316T3 (tr)
TR (1) TR201910084T4 (tr)
WO (1) WO2013022797A1 (tr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778910B (zh) 2006-11-08 2014-05-28 分子制药洞察公司 谷氨酸的异质二聚体
NZ616957A (en) 2007-02-19 2015-06-26 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
WO2010065899A2 (en) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
WO2017053268A1 (en) * 2015-09-21 2017-03-30 Serrano-Ojeda Pedro Anastacio Glutamine-high z element compounds for treating cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
WO2013103813A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
ES2738474T3 (es) 2013-01-14 2020-01-23 Molecular Insight Pharm Inc Radiofármacos a base de triazina y agentes radioimagenológicos
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
TN2016000137A1 (en) * 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA035171B1 (ru) * 2013-11-14 2020-05-08 Эндосайт, Инк. Конъюгаты на основе связывающихся с psma лигандов или ингибиторов psma для позитронно-эмиссионной томографии
US20160303258A1 (en) * 2013-12-03 2016-10-20 Millennium Pharmaceuticals, Inc. Compounds and compositions for imaging gcc-expressing cells
EP3536345A1 (en) * 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
CA2959726A1 (en) * 2014-09-08 2016-03-17 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3011976A1 (en) 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10869940B2 (en) 2015-06-12 2020-12-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted photoacoustic compounds, formulations, and uses thereof
HUE053064T2 (hu) 2015-09-30 2021-06-28 Deutsches Krebsforsch Prosztataspecifikus membránantigén (PSMA) 18F-címkézett inhibitorai és azok alkalmazása képalkotó ágensként prosztatarákkal
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
TR201813644T1 (tr) 2016-03-22 2018-11-21 Univ Johns Hopkins Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar.
FI127538B (en) * 2016-06-22 2018-08-31 Dextech Medical Ab MODIFIED Dextran Conjugates
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
DE212016000299U1 (de) * 2016-12-15 2019-09-05 The European Atomic Energy Community (Euratom), Represented By The European Commission Behandlung vpm PMSA-exprimierenden Krebsarten
JP7396897B2 (ja) * 2017-04-05 2023-12-12 コーネル ユニバーシティー 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US11629201B2 (en) 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
MX2019015616A (es) * 2017-06-19 2020-02-26 Futurechem Co Ltd Compuesto marcado con 18f para diagnostico de cancer de prostata y uso de este.
WO2018236115A1 (ko) * 2017-06-19 2018-12-27 (주)퓨쳐켐 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
WO2019115684A1 (en) * 2017-12-13 2019-06-20 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
MX2020008247A (es) * 2018-02-06 2021-02-26 Univ Johns Hopkins Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer.
MX2020010266A (es) * 2018-03-30 2020-11-06 Futurechem Co Ltd Radiofarmaco dirigido a antigeno de membrana especifico de prostata (psma) para diagnosticar y tratar el cancer de prostata.
EP3590911A1 (en) * 2018-07-01 2020-01-08 Studiengesellschaft Kohle MbH Reagent and process for the site-specific deoxyfluorination of peptides
EP3856261A1 (en) 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
US11944690B2 (en) 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CN113710286A (zh) * 2019-02-14 2021-11-26 海德堡鲁普雷希特卡尔斯大学 具有改善的组织特异性的前列腺特异性膜抗原(psma)配体
JP2022520798A (ja) 2019-02-14 2022-04-01 ドイチェス クレブスフォルシュンクスツェントルム アミラーゼ切断可能なリンカーを含む前立腺特異的膜抗原（ｐｓｍａ）リガンド
WO2020220023A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
US20230072421A1 (en) 2019-07-25 2023-03-09 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation CONTRAST AGENTS DIRECTED AGAINST PSMA
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
US20230406847A1 (en) 2020-11-12 2023-12-21 Abx Advanced Biochemical Compounds Gmbh Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
JP2024503908A (ja) 2021-01-22 2024-01-29 バイエル アクチェンゲゼルシャフト Ｌｒｒｃ１５抗体およびそのコンジュゲート
AU2022293573A1 (en) * 2021-06-17 2023-12-14 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
CN115745903A (zh) * 2021-09-03 2023-03-07 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
WO2023086833A1 (en) * 2021-11-09 2023-05-19 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2023208928A1 (en) 2022-04-26 2023-11-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dosage of psma-ligands for fluorescence based detection of cancerous tissue
WO2023222680A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
WO2023222681A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands with improved renal clearance
WO2023222682A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
WO2023222679A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
WO2023231452A1 (zh) * 2023-02-14 2023-12-07 北京师范大学 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408079B2 (en) * 2002-01-10 2008-08-05 The Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
CN101778910B (zh) * 2006-11-08 2014-05-28 分子制药洞察公司 谷氨酸的异质二聚体
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
CA2745955C (en) * 2008-12-05 2017-05-23 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium- bis (heteroaryl) complexes and methods of use thereof for inhibiting psma
HUE059796T2 (hu) 2009-03-19 2022-12-28 Univ Johns Hopkins PSMA-t célzó vegyületek és alkalmazásaik

Also Published As

Publication number Publication date
EP2739316A4 (en) 2015-03-11
US9388144B2 (en) 2016-07-12
AU2012294639A1 (en) 2014-02-27
CA2844151C (en) 2022-11-29
HUE045028T2 (hu) 2019-12-30
AU2012294639B2 (en) 2017-10-26
US20150078998A1 (en) 2015-03-19
US20130034494A1 (en) 2013-02-07
JP2014524419A (ja) 2014-09-22
ES2732060T3 (es) 2019-11-20
AU2012294639A8 (en) 2014-03-06
WO2013022797A1 (en) 2013-02-14
EP3505192A1 (en) 2019-07-03
EP2739316B1 (en) 2019-04-10
EP2739316A1 (en) 2014-06-11
JP5843338B2 (ja) 2016-01-13
US8926944B2 (en) 2015-01-06
PL2739316T3 (pl) 2019-09-30
CA2844151A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
TR201910084T4 (tr) Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri.
CY1122278T1 (el) Αντι il-36r αντισωματα
MA34091B1 (fr) Anticorps anti-cd40
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
TR201904340T4 (tr) Yeni bileşikler.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201590979A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201692271A1 (ru) Терапевтически активные соединения и способы их применения
TR201911139T4 (tr) Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
UA110338C2 (en) Chemical compounds
BR112014013526A8 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
EA201270149A1 (ru) Ингибиторы bace
TR201901930T4 (tr) Topraktaki mikrobiyal aktivitenin geliştirilmesine yönelik bir yöntem.
MY169043A (en) New dihydroquinoline-2-one derivatives
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
CR20130539A (es) Triazolopiridinas
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201290642A1 (ru) Соединения и способы
EA201492023A1 (ru) Регуляторы пути комплемента и их применение